We observed a significant difference (p = 0.02) in PD-L1/TIGIT co-expression in tumor-infiltrating cells from patients with triple-negative tumors (33.3%) compared to patients with Luminal A (10.5%), Luminal B (20.0%) and Her2+ (12.5%) tumors. This evidence concerns the gene ERBB2 and neoplasm.